VIRxSYS CORPORATION

INVESTIGATIVE NEW DRUG PROTOCOL

PROTOCOL NUMBER VRX 496-01-01

A Phase 1 Open-Label Clinical Trial of the Safety and Tolerability of Single Escalating Doses of Autologous T Cells Transduced with VRX496 in HIV Positive Patient-Subjects

PRESENTATION FOR THE NIH / OBA

SEPTEMBER 6, 2001

379463 [illegible]

Contents

1. Reviewers Questions and Comments

2. Responses to Reviewers' Questions and Comments

3. Slide Presentation

4. Biodistribution Study and Interim Report

5. Patient Consent Form

6. Clinical Protocol